Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $3.28 in the prior trading day, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $3.22, down -1.83%. In other words, the price has decreased by -$1.83 from its previous closing price. On the day, 0.72 million shares were traded. ABUS stock price reached its highest trading level at $3.27 during the session, while it also had its lowest trading level at $3.16.
Ratios:
Our goal is to gain a better understanding of ABUS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.02 and its Current Ratio is at 7.02. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 14 ’24 when MANCHESTER KEITH S sold 8,846 shares for $3.69 per share. The transaction valued at 32,637 led to the insider holds 46,069 shares of the business.
Sims Karen sold 4,358 shares of ABUS for $10,078 on Feb 02 ’24. The Chief Medical Officer now owns 125,542 shares after completing the transaction at $2.31 per share. On Feb 02 ’24, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 610164224 and an Enterprise Value of 489130240. For the stock, the TTM Price-to-Sale (P/S) ratio is 90.53 while its Price-to-Book (P/B) ratio in mrq is 5.71. Its current Enterprise Value per Revenue stands at 72.55 whereas that against EBITDA is -6.341.
Stock Price History:
The Beta on a monthly basis for ABUS is 1.78, which has changed by 0.36440682 over the last 52 weeks, in comparison to a change of 0.22677135 over the same period for the S&P500. Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is -7.29%, while the 200-Day Moving Average is calculated to be -8.05%.
Shares Statistics:
The stock has traded on average 897.34K shares per day over the past 3-months and 841040 shares per day over the last 10 days, according to various share statistics. A total of 189.44M shares are outstanding, with a floating share count of 147.38M. Insiders hold about 22.22% of the company’s shares, while institutions hold 53.49% stake in the company. Shares short for ABUS as of 1735603200 were 5948529 with a Short Ratio of 6.63, compared to 1732838400 on 5821160. Therefore, it implies a Short% of Shares Outstanding of 5948529 and a Short% of Float of 3.9800000000000004.
